Zacks Investment Research downgraded shares of ONCOLYTICS BIO (ONCY) from OUTPERFORM to NEUTRAL on September 03, 2013, with a target price of $3.00.
Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ONCOLYTICS BIO (ONCY),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment